Biotech Valneva eyes growth inflection with Covid vaccine
CEO Thomas Lingelbach confident of European approval, but shuns 'pandemic stock' label.
Singapore
FRENCH biotech Valneva, a manufacturer of vaccines for travellers, was once a sleepy stock, with a market capitalisation of just 236.8 million euros (S$351.8 million) in end-2019. But entering the Covid-19 vaccine race has swept it into the public eye.
In 2020, Valneva unveiled plans to develop a Covid-19 vaccine based on the more mature non-mRNA technology. It has since faced many ups and downs, from positive trial results and emergency approval in Bahrain, to a cancelled contract with the United Kingdom.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
BlackRock warns weak yen deters foreigners from Japan stocks
Temasek-backed Climate Impact X to launch market intelligence service
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Asia’s aversion to rate cuts steers EM bond investors away
China takes advantage of cheap gas and coal to rebuild stocks
ANZ faces regulator probe on Australia government bond sale